INVEX Therapeutics Ltd (IXC) — Cash Flow-to-Debt Ratio
INVEX Therapeutics Ltd (IXC) has a Cash Flow-to-Debt Ratio of -4.42x as of December 2025, meaning its operating cash flow of AU$-779.73K could theoretically repay -4% of its total liabilities (AU$176.49K) in one year. See IXC working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
INVEX Therapeutics Ltd Cash Flow-to-Debt Ratio (2019–2025)
Historical debt coverage capacity for INVEX Therapeutics Ltd across 7 annual periods. Also explore IXC net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for INVEX Therapeutics Ltd (2019–2025)
Year-by-year debt coverage analysis for INVEX Therapeutics Ltd. For market capitalisation and broader financial context, see market cap of INVEX Therapeutics Ltd.
| Year | CF-to-Debt Ratio | Operating CF (AUD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.96x | AU$-652.57K | AU$220.59K | ▲ +47.8% |
| 2024 | -5.66x | AU$-2.44 Million | AU$431.63K | ▼ -29.6% |
| 2023 | -4.37x | AU$-6.87 Million | AU$1.57 Million | ▼ -29.9% |
| 2022 | -3.36x | AU$-3.38 Million | AU$1.00 Million | ▼ -32.0% |
| 2021 | -2.55x | AU$-1.68 Million | AU$658.61K | ▼ -220.3% |
| 2020 | -0.80x | AU$-1.60 Million | AU$2.02 Million | ▼ -223.4% |
| 2019 | -0.25x | AU$-230.13K | AU$935.49K | — |